Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02954159 · ClinicalTrials.gov registry record · Phase 3
Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC
A Phase 3 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT02954159 is a Phase 3 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 4 participants.
The verdict
NCT02954159, a Phase 3 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
The aim of this study is to assess if a combination therapy of tacrolimus and vedolizumab is superior to vedolizumab monotherapy for induction of remission in moderate to severe UC, and its effect on long and short-term outcomes including colectomy rate. Secondary aim of this study is to assess the safety of tacrolimus as an induction agent in patients with UC.
Interventions
- OTHER Placebo
- DRUG Vedolizumab
- DRUG Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-05-18 |
| Est. Completion | 2019-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02954159
The ClinicalTrials.gov registry entry for NCT02954159 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02954159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02954159 about?
NCT02954159 is a clinical study titled "Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC". The aim of this study is to assess if a combination therapy of tacrolimus and vedolizumab is superior to vedolizumab monotherapy for induction of remission in moderate to severe UC, and its effect on long and short-term outcomes including colectomy rate. Secondary aim of this study is to assess the ...
What is the current status of trial NCT02954159?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2017-05-18. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT02954159?
The interventions under investigation include: Placebo (OTHER), Vedolizumab (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT02954159?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.